8 Investor presentation First six months of 2023 GLP-1 class expansion accelerate 2023 with volume growth across Weekly NBRx scripts ( ‘ 000s) 90 US GLP-1 weekly NBRx prescriptions 60 30 0 Jul 2021 Ozempic ® Rybelsus ® Victoza ® Jul 2023 NN GLP-1 du NBRx: New-to-brand prescriptions; TRx: Total prescriptions; NN: Novo Nordisk; Scripts: Prescriptions; US: United States Note: Class growth calculated as Q2 2023 vs Q2 2022 Source: IQVIA Xponent, NBRx data from week ending 21 Jul 2023. TRx data from week ending 21 Jul 2023. Each data points represe
Download PDF file